Thus, the results suggest that rLAS-uPA treatment may be associated with clinically relevant benefits in some dogs with brain tumors and mild to moderate neurological dysfunction by delaying tumor progression without substantially reducing tumor volume. Here, PLAU is linked to neoplasm.